Sionna Therapeutics, Inc.
SIONHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeSionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). The $162.8M market capitalization puts SION squarely in micro-cap range for its industry. It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Market Cap
$162.8M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-1.61
EPS (TTM)
$-2.16
EPS (Fwd)
$-2.23
ROE
-32.3%
ROA
-21.5%
Cash
$211.0M
Total Debt
$8.1M
Free CF
-$45.4M
52W Change
-90.6%
Annual Financials
Cash vs Debt
Where SION stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SION finished 86.36% below its 150-day moving average ($29.40) and 87.34% below its 200-day moving average ($31.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SION overbought or oversold?
At the October 20, 2026 close, SION's RSI(14) was 20.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $211.0M in cash and $8.1M in debt, SION maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$45.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -32.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SION's risk profile alongside its fundamentals and technical indicators provides a more complete picture.